Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
- PMID: 25336925
- PMCID: PMC4199975
- DOI: 10.2147/DDDT.S67961
Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
Abstract
Aim: Protein kinase B (AKT) signaling frequently is deregulated in human cancers and plays an important role in nasopharyngeal carcinoma (NPC). This preclinical study investigated the effect of MK-2206, a potent allosteric AKT inhibitor, on human NPC cells in vitro and in vivo.
Methods: The effect of MK-2206 on the growth and proliferation of CNE-1, CNE-2, HONE-1, and SUNE-1 cells was assessed by Cell Counting Kit 8 and colony formation assay. Flow cytometry was performed to analyze cell cycle and apoptosis. The effects of MK-2206 on the AKT pathway were analyzed by Western blotting. Autophagy induction was evaluated via electron microscopy and Western blot. To test the effects of MK-2206 in vivo, CNE-2 cells were subcutaneously implanted into nude mice. Tumor-bearing mice were treated orally with MK-2206 or placebo. Tumors were harvested for immunohistochemical analysis.
Results: In vitro, MK-2206 inhibited the four NPC cell line growths and reduced the sizes of the colonies in a dose-dependent manner. At 72 and 96 hours, the half maximal inhibitory concentration (IC50) values of MK-2206 in CNE-1, CNE-2, and HONE-1 cell lines were 3-5 μM, whereas in SUNE-1, IC50 was less than 1 μM, and MK-2206 induced cell cycle arrest at the G1 phase. However, our study found no evidence of apoptosis. MK-2206 induced autophagy in NPC cells, as evidenced by electron microscopy and Western blot, and inhibited the growth of tumors that were subcutaneously implanted in mice. Inhibition of downstream phosphorylation through the PRAS40 and S6 pathways seems to be the main mechanism for the MK-2206-induced growth inhibition.
Conclusion: Our preclinical study suggests that MK-2206's antiproliferative effect may be useful for NPC treatment; however, strategies for reinforcing this effect are needed to maximize clinical benefit.
Keywords: AKT inhibitor; MK-2206; nasopharyngeal carcinoma.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4199975/bin/dddt-8-1827Fig1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4199975/bin/dddt-8-1827Fig2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4199975/bin/dddt-8-1827Fig3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4199975/bin/dddt-8-1827Fig4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4199975/bin/dddt-8-1827Fig5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4199975/bin/dddt-8-1827Fig6.gif)
Similar articles
-
Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma.Drug Des Devel Ther. 2018 Aug 29;12:2655-2663. doi: 10.2147/DDDT.S169952. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30214154 Free PMC article.
-
Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.Invest New Drugs. 2013 Jun;31(3):567-75. doi: 10.1007/s10637-012-9896-5. Epub 2012 Nov 11. Invest New Drugs. 2013. PMID: 23143779
-
Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.PLoS One. 2012;7(7):e41593. doi: 10.1371/journal.pone.0041593. Epub 2012 Jul 24. PLoS One. 2012. PMID: 22911820 Free PMC article.
-
Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway.Cancer Chemother Pharmacol. 2020 Jun;85(6):1097-1108. doi: 10.1007/s00280-020-04083-3. Epub 2020 May 24. Cancer Chemother Pharmacol. 2020. PMID: 32449143
-
Akt Pathway Inhibitors.Curr Top Med Chem. 2020;20(10):883-900. doi: 10.2174/1568026620666200224101808. Curr Top Med Chem. 2020. PMID: 32091335 Review.
Cited by
-
CircLASP1 silence strengthens the therapeutic effects of MK-2206 on nasopharyngeal cancer through upregulating miR-625.Cancer Sci. 2023 May;114(5):2123-2138. doi: 10.1111/cas.15725. Epub 2023 Mar 1. Cancer Sci. 2023. PMID: 36644819 Free PMC article.
-
Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.J Med Chem. 2022 Oct 27;65(20):14237-14260. doi: 10.1021/acs.jmedchem.2c01454. Epub 2022 Oct 5. J Med Chem. 2022. PMID: 36197750 Free PMC article.
-
Acetylshikonin induces autophagy-dependent apoptosis through the key LKB1-AMPK and PI3K/Akt-regulated mTOR signalling pathways in HL-60 cells.J Cell Mol Med. 2022 Mar;26(5):1606-1620. doi: 10.1111/jcmm.17202. Epub 2022 Feb 2. J Cell Mol Med. 2022. PMID: 35106915 Free PMC article.
-
An overview of kinase downregulators and recent advances in discovery approaches.Signal Transduct Target Ther. 2021 Dec 20;6(1):423. doi: 10.1038/s41392-021-00826-7. Signal Transduct Target Ther. 2021. PMID: 34924565 Free PMC article. Review.
-
The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis.J Exp Clin Cancer Res. 2021 Dec 10;40(1):390. doi: 10.1186/s13046-021-02191-3. J Exp Clin Cancer Res. 2021. PMID: 34893086 Free PMC article.
References
-
- Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455–7464. - PubMed
-
- Altun M, Fandi A, Dupuis O, Cvitkovic E, Krajina Z, Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys. 1995;32(3):859–877. - PubMed
-
- Cheng SH, Jian JJ, Tsai SY, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 2000;48(5):1323–1330. - PubMed
-
- Yamashita S, Kondo M, Hashimoto S. Squamous cell carcinoma of the nasopharynx. An analysis of failure patterns after radiation therapy. Acta Radiol Oncol. 1985;24(4):315–320. - PubMed
-
- Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20(9):2240–2250. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous